Physiologically-Based Pharmacokinetic (PBPK) Modeling and Risk Assessment

[1]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[2]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[3]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[4]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[5]  E J O'Flaherty,et al.  Physiologically based models for bone-seeking elements. V. Lead absorption and disposition in childhood. , 1995, Toxicology and applied pharmacology.

[6]  R. Coulombe,et al.  Pharmacokinetics in Risk Assessment , 1996 .

[7]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[8]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .

[9]  Melvin E Andersen,et al.  New directions in incidence-dose modeling. , 2005, Trends in biotechnology.

[10]  Harvey J Clewell,et al.  Perchlorate and Radioiodide Kinetics Across Life Stages in the Human: Using PBPK Models to Predict Dosimetry and Thyroid Inhibition and Sensitive Subpopulations Based on Developmental Stage , 2007, Journal of toxicology and environmental health. Part A.